TM1
Terra Metals Limited
🇦🇺 ASX
⛏️ MINING
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-6.22%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Terra Metals Ltd is a AU-based company operating in Metals & Mining industry. The company is headquartered in Perth, Western Australia and currently employs 0 full-time employees. The company went IPO on 2012-12-20. Terra Metals Limited, formerly GCX Metals Limited, is a diversified critical metals explorer focused on exploring and developing its Western Australian projects. The firm is primarily focused on the exploration of its flagship Dante Cu-PGE-Au-Ni project in Western Australia. The Dante Project contains large-scale magmatic copper-gold (and palladium-nickel) targets, as well as extensive outcropping PGE-Au-Cu reefs and is situated in the same geological complex and 15 kilometers (km) from the 390 metric tons (Mt) Nebo-Babel nickel-copper deposit and 10km from the 120 Mt Succoth copper deposit. The company is also conducting exploration activities at its Onslow Cu-Au Project and the Southern Cross Li-REE Project in Western Australia. The Onslow Project covers over 548 square kilometers (km2) and comprises three tenements located in the northwestern extension of the Capricorn Orogen. The Southern Cross Project comprises four tenements covering approximately 800km2 in Koolyanobbing shear zone.
📈 Performance
Price History
-86.22%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.03
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in TM1
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in TM1
N/A
TM1 investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in TM1 also invest in...
Want more shares? Try these...
Tambourah Metals Ltd. engages in exploration of gold, nickel and platinum group elements. The company is headquartered in Perth, Western Australia. The company went IPO on 2021-08-12. The Company’s Tambourah Project is located about 85 kilometers (km) southwest of Marble Bar in the East Pilbara district of Western Australia. The Tambourah Project covers an area of approximately 1520 hectares (ha) and comprises an exploration license (E 45/4597), and four prospecting licenses (P 45/2868-I, P 45/2869-I, P 45/2870-I, P 45/2871-I). Its Cheela gold project is approximately 50 km west of Paraburdoo in the Ashburton district and covers approximately 70 km of the west-northwest trending Nanjilgardy Fault. The Russian Jack Project is located about 15 km southwest of Nullagine. Its Nullagine Project is located about 11 km east of Nullagine. Its TMB Nullagine project is located about 11 km from the town of Nullagine. The Company’s other projects include Shaw River, Tambourah North, WH Sth, and Achilles Ni-PGE-Cu project, among others.
📊 Share price
$0.03 AUD
⛏️ MINING
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-15. The firm is focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. The company is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). Its pipelines include TLX591, TLX592 (alpha-RADmAb), TLX591-CDx, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx. TLX591 is a radio antibody-drug conjugate (rADC) directed at prostate-specific membrane antigen (PSMA). Its product QUANTM Irradiation System (QIS), enables production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu).
🙌 Performance (5Yr p.a)
225.43%
📊 Share price
$22.58 AUD
🧬 BIOTECHNOLOGY